Association of Multiple Sclerosis with Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies
American Journal of Clinical Dermatology, pp 1–8; DOI https://doi.org/10.1007/s40257-018-0399-9
Chia-Yu Liu Tao-Hsin Tung Chin-Yu Lee Kuo-Hsuan Chang Shu-Hui Wang Ching-Chi Chi
High Dose Vitamin D has been proven to treat both auto-immune diseases (along with many others)
- 35,000 IU vitamin D daily for 6 months helped ALL psoriasis suffers (106 ng) – Brazil March 2013
- Multiple Sclerosis - Coimbra Protocol (high-dose Vitamin D) - by one of the 120 doctors of 20,000 patients - Dec 2018
Autoimmune category starts with
162 items in Autoimmune category
- Vitamin D and MS Asthma RA Diabetes Gut Allergy Hay Fever Muscular Dystrophy Lupus Psoriasis
- Autoimmune disease clusters run in families having low D
- How Vitamin D reduces inflammation, improves immunity and fights autoimmunity – review Dec 2018
- 120 doctors and 20,000 MS patients using high dose Vitamin D Dec 2018
- Vitamin D has treated Multiple Sclerosis and autoimmune diseases for 16 years – Coimbra April 2018
- Vitamin D Receptor is associated in over 40 autoimmune studies
- Many autoimmune diseases associated with low vitamin D or poor Vit D genes – July 2019
- Multiple Sclerosis increases risk of Psoriasis by 1.9X (both associated with low vitamin D) – meta-analysis Oct 2018
- How UVB reduces autoimmune diseases such as Multiple Sclerosis – April 2014
- Vitamin D at CureTogether: Fibromyalgia, MS, Psorasis, etc - Dec 2013
- UV produces more than vitamin D – Aug 2011
- Vitamin D patent for treating immune system diseases
Background: Previous studies have reported the occurrence of psoriasis together with multiple sclerosis (MS). Although similar predisposing genes and pathomechanisms have been hypothesized, the relationship between the two remains obscure.
Objective: The aim of this systematic review and meta-analysis was to investigate the association between psoriasis and MS.
We searched MEDLINE, Embase, and CENTRAL in July 2018 for case–control, cross-sectional, or cohort studies that examined either the odds or risk of psoriasis in subjects with multiple sclerosis. The risk of bias of included studies was assessed using the Newcastle–Ottawa Scale. A random-effects model meta-analysis was used to calculate the odds ratio (OR) for case–control/cross-sectional studies and hazard ratio (HR) for cohort studies.
We included 10 publications that reported a total of 11 studies (5 case–control, 4 cross-sectional and 2 cohort studies). The case–control and cross-sectional studies included 18,456 MS patients and 870,149 controls, while the two cohort studies involved 25,187 MS patients and 227,225 controls in total. Three studies were rated with a high risk of bias in comparability, non-response rate, and selection of controls. MS was associated with increased odds (OR 1.29; 95% confidence interval CI 1.14–1.45) and risk for psoriasis (HR 1.92; 95% CI 1.32–2.80).
Conclusion: Patients with MS display both increased prevalence and incidence of psoriasis.
The connection between multiple sclerosis and psoriasis Dermatology Times
- "Medical specialists should be aware of the risk of developing psoriasis in patients with multiple sclerosis. Because both disorders are attributed to autoimmune mechanisms, we suggest that dermatology specialists may need not only neurology, but also rheumatology consultations. Further laboratory or imaging studies may be necessary for psoriatic patients in whom neurological symptoms appear,"
- "Previous studies have established strong evidence that Epstein-Barr virus is related to multiple sclerosis, although few studies have investigated the connection between Epstein-Barr virus and psoriasis. Investigators hypothesized that Epstein-Barr virus might induce cutaneous manifestations, as herpes simplex virus does, and these manifestations could result in the immunopathogenesis of psoriasis."
Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013;19(2 Suppl):S15–20.
Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3–4):132–41. https://doi.org/10.1159/000360528.
Bogdanos DP, Smyk DS, Rigopoulou EI, Sakkas LI, Shoenfeld Y. Infectomics and autoinfectomics: a tool to study infectious-induced autoimmunity. Lupus. 2015;24(4–5):364–73. https://doi.org/10.1177/0961203314559088.
Procaccini C, De Rosa V, Pucino V, Formisano L, Matarese G. Animal models of multiple sclerosis. Eur J Pharmacol. 2015;759:182–91. https://doi.org/10.1016/j.ejphar.2015.03.042.
Gonsette RE. Self-tolerance in multiple sclerosis. Acta Neurol Belg. 2012;112(2):133–40. https://doi.org/10.1007/s13760-012-0061-x.
LeVine SM. The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hypotheses. 1992;39(3):271–4.
Files DK, Jausurawong T, Katrajian R, Danoff R. Multiple sclerosis. Prim Care. 2015;42(2):159–75. https://doi.org/10.1016/j.pop.2015.01.007.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85. https://doi.org/10.1038/jid.2012.339.
Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26(Suppl 2):3–11. https://doi.org/10.1111/j.1468-3083.2011.04410.x.
Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013;87(9):626–33.
Della Valle V, Maggioni M, Carrera C, Cattaneo A, Marzano AV, Damiani G. A mysterious abdominal pain during active psoriasis. Internal and emergency medicine. 2017. https://doi.org/10.1007/s11739-017-1765-y.
Damiani G, Franchi C, Pigatto P, Altomare A, Pacifico A, Petrou S, et al. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents. World J Hepatol. 2018;10(2):329–36. https://doi.org/10.4254/wjh.v10.i2.329.
Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver illness and psoriatic patients. Biomed Res Int. 2018;2018:12. https://doi.org/10.1155/2018/3140983.
Tsai TF, Lee CH, Huang YH, Chi CC, Chang YT, Wong TW, et al. Taiwanese Dermatological Association consensus statement on management of psoriasis. Dermatol Sin. 2017;35(2):66–77. https://doi.org/10.1016/j.dsi.2017.01.002.
Damiani G, Radaeli A, Olivini A, Calvara-Pinton P, Malerba M. Increased airway inflammation in patients with psoriasis. Br J Dermatol. 2016;175(4):797–9. https://doi.org/10.1111/bjd.14546.
Weidinger S, Willis-Owen SA, Kamatani Y, Baurecht H, Morar N, Liang L, et al. A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis. Hum Mol Genet. 2013;22(23):4841–56. https://doi.org/10.1093/hmg/ddt317.
Malerba M, Damiani G, Radaeli A, Ragnoli B, Olivini A, Calzavara-Pinton PG. Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma. Br J Dermatol. 2015;173(6):1544–5. https://doi.org/10.1111/bjd.13988.
Malerba M, Radaeli A, Olivini A, Damiani G, Ragnoli B, Montuschi P, et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed Res Int. 2014;2014:271918. https://doi.org/10.1155/2014/271918.
Shapiro J, Cohen AD, Weitzman D, Tal R, David M. Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis. J Am Acad Dermatol. 2012;66(2):252–8. https://doi.org/10.1016/j.jaad.2010.11.046.
Chi CC, Wang J, Chen YF, Wang SH, Chen FL, Tung TH. Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study. J Dermatol Sci. 2015;78(3):232–8. https://doi.org/10.1016/j.jdermsci.2015.03.012.
Chi CC, Tung TH, Wang J, Lin YS, Chen YF, Hsu TK et al. Risk of uveitis among people with psoriasis: a nationwide cohort study. JAMA Ophthalmol. 2017. https://doi.org/10.1001/jamaophthalmol.2017.0569.
Boehncke WH, Sterry W. Psoriasis–a systemic inflammatory disorder: clinic, pathogenesis and therapeutic perspectives. J Dtsch Dermatol Ges. 2009;7(11):946–52. https://doi.org/10.1111/j.1610-0387.2009.07083.x.
Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):559–68. https://doi.org/10.1586/14737167.2014.914437.
Rencz F, Gulacsi L, Remenyik E, Szegedi A, Hollo P, Karpati S, et al. Subjective expectations regarding life expectancy and health-related quality of life in moderate to severe psoriasis patients. Value Health. 2014;17(7):A611. https://doi.org/10.1016/j.jval.2014.08.2142.
Kwok T, Jing Loo W, Guenther L. Psoriasis and multiple sclerosis: is there a link? J Cutan Med Surg. 2010;14(4):151–5. https://doi.org/10.2310/7750.2010.09063.
Dobson R, Giovannoni G. Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. J Neurol. 2013;260(5):1272–85. https://doi.org/10.1007/s00415-012-6790-1.
Opazo MC, Ortega-Rocha EM, Coronado-Arrazola I, Bonifaz LC, Boudin H, Neunlist M, et al. Intestinal microbiota influences non-intestinal related autoimmune diseases. Front Microbiol. 2018;9:432. https://doi.org/10.3389/fmicb.2018.00432.
Wells G SB, O’Connell J, Robertson J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. 2011. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: the nordic cochrane centre, The Cochrane Collaboration. 2014.
Fellner A, Dano M, Regev K, Mosek A, Karni A. Multiple sclerosis is associated with psoriasis. A case-control study. J Neurol Sci. 2014;338(1–2):226–8. https://doi.org/10.1016/j.jns.2014.01.003.
Henderson RD, Bain CJ, Pender MP. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci. 2000;7(5):434–7. https://doi.org/10.1054/jocn.2000.0693.
Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler. 2010;16(7):855–61. https://doi.org/10.1177/1352458510369146.
Laroni A, Calabrese M, Perini P, Albergoni MP, Ranzato F, Tiberio M, et al. Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. J Neurol. 2006;253(5):636–9. https://doi.org/10.1007/s00415-006-0084-4.
Midgard R, Gronning M, Riise T, Kvale G, Nyland H. Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol Scand. 1996;93(5):322–8.
Ramagopalan SV, Dyment DA, Valdar W, Herrera BM, Criscuoli M, Yee IM, et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol. 2007;6(7):604–10. https://doi.org/10.1016/s1474-4422(07)70132-1.
Marrie RA, Patten SB, Tremlett H, Wolfson C, Leung S, Fisk JD. Increased incidence and prevalence of psoriasis in multiple sclerosis. Mult Scler Relat Disord. 2017;13:81–6. https://doi.org/10.1016/j.msard.2017.02.012.
Edwards LJ, Constantinescu CS. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler. 2004;10(5):575–81. https://doi.org/10.1191/1352458504ms1087oa.
Guido N, Cices A, Ibler E, Huynh T, Majewski S, Sable K et al. Multiple sclerosis association with psoriasis: a large U.S. population, single centre, retrospective cross-sectional study. J Eur Acad Dermatol Venereol. 2017;31(9):e397–e8. https://doi.org/10.1111/jdv.14205.
Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery S. Shared genetic factors may not explain the raised risk of comorbid inflammatory diseases in multiple sclerosis. Mult Scler. 2012;18(10):1430–6. https://doi.org/10.1177/1352458512438240.
Anagnostouli M, Anagnostoulis G, Katsavos S, Panagiotou M, Kararizou E, Davaki P. HLA-DRB1 15:01 and Epstein-Barr virus in a multiple sclerosis patient with psoriasis, nasopharyngeal and breast cancers. Lessons for possible hidden links for autoimmunity and cancer. J Neurol Sci. 2014;339(1–2):26–31. https://doi.org/10.1016/j.jns.2014.02.003.
Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S2–6.
Wang X, Xu K, Chen S, Li Y, Li M. Role of interleukin-37 in inflammatory and autoimmune diseases. IJI. 2018;15(3):165–74. https://doi.org/10.22034/iji.2018.39386.
Yadav SK, Mindur JE, Ito K, Dhib-Jalbut S. Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol. 2015;28(3):206–19. https://doi.org/10.1097/wco.0000000000000205.
Kouris A, Pistiki A, Katoulis A, Georgitsi M, Giatrakou S, Papadavid E, et al. Proinflammatory cytokine responses in patients with psoriasis. Eur Cytokine Netw. 2014;25(4):63–8. https://doi.org/10.1684/ecn.2014.0358.
Tahvili S, Zandieh B, Amirghofran Z. The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis. Int J Dermatol. 2015;54(7):e254–60. https://doi.org/10.1111/ijd.12834.
Wu Q, Wang Q, Mao G, Dowling CA, Lundy SK, Mao-Draayer Y. Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1/Th17 and Th2 in multiple sclerosis patients. Journal of immunology (Baltimore, Md: 1950). 2017;198(8):3069–3080. https://doi.org/10.4049/jimmunol.1601532.
Xu Z, Zhang F, Sun F, Gu K, Dong S, He D. Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev. 2015(4):Cd011076. https://doi.org/10.1002/14651858.cd011076.pub2.
Mrowietz U, Barker J, Boehncke WH, Iversen L, Kirby B, Naldi L, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018;32(S3):3-14. https://doi.org/10.1111/jdv.15218.
Heine G, Drozdenko G, Grun JR, Chang HD, Radbruch A, Worm M. Autocrine IL-10 promotes human B-cell differentiation into IgM- or IgG-secreting plasmablasts. Eur J Immunol. 2014;44(6):1615–21. https://doi.org/10.1002/eji.201343822.
Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms. Diagnoses and cell-based therapy. Cell J. 2017;19(1):1–10.
Ho P, Barton A, Worthington J, Plant D, Griffiths CEM, Young HS, et al. Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis. 2008;67(5):677–82. https://doi.org/10.1136/ard.2007.071399.
Hollenbach JA, Oksenberg JR. The immunogenetics of multiple sclerosis: a comprehensive review. J Autoimmun. 2015;64:13–25. https://doi.org/10.1016/j.jaut.2015.06.010.
Javan MR, Shahraki S, Safa A, Zamani MR, Salmaninejad A, Aslani S. An interleukin 12 B single nucleotide polymorphism increases IL-12p40 production and is associated with increased disease susceptibility in patients with relapsing-remitting multiple sclerosis. Neurol Res. 2017;39(5):435–41. https://doi.org/10.1080/01616412.2017.1301623.
Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273–90. https://doi.org/10.1086/511051.
Lucas RM, Byrne SN, Correale J, Ilschner S, Hart PH. Ultraviolet radiation, vitamin D and multiple sclerosis. Neurodegener Dis Manag. 2015;5(5):413–24. https://doi.org/10.2217/nmt.15.33.
896 visitors, last modified 13 Dec, 2018, URL: